… in more detail, including why the DPI regimen with the rivaroxaban vascular dose was
developed for vascular protection in a broad spectrum of patients with atherosclerotic disease. …

… antiplatelet treatment regimens with aspirin plus a P2Y12 inhibitor to dual pathway inhibition
with low-dose rivaroxaban in adjunct to aspirin in patients with coronary artery disease: the …

… A parallel line of research in patients with atherosclerotic disease manifestations using a
DOAC in combination with antiplatelet therapy with the aim of reducing ischaemic recurrences …

… atherosclerosis is a systemic disease, many patients with known ASCVD in one vascular …
of rivaroxaban has been labelled as the ‘vascular protection’ dose to differentiate this regimen …

… shown to reduce atherosclerotic plaque progression in mouse models and to … plaque stability
by thickening the protective fibrous cap. Whether rivaroxaban affects atherosclerotic plaque …

… events in patients with stable atherosclerotic disease. However… it compares to standard dual
antiplatelet therapy (DAPT). … cohorts of patients (n = 40) with stable atherosclerotic disease—…

… In arterial thrombosis, thrombin generation is triggered by tissue factor (TF) after atherosclerotic
plaque rupture. Thrombin activates platelets by binding and cleaving protease-activated …

… select patients thoughtfully for dual pathway inhibitor therapy. … the patients most likely to
benefit from dual pathway inhibitor … of mortality achieved with dual pathway inhibition was (as …

… Rationale for the use of rivaroxaban for CV protection The underlying pathophysiology of
atherothrombosis is the rupture or erosion of an atherosclerotic plaque which exposes the …

Background: In the COMPASS trial, the combination of acetylsalicylic acid (ASA) plus 2.5
mg rivaroxaban twice daily (dual-pathway inhibition, DPI) has been shown to be superior to …